CytomX Therapeutics Inc（CTMX）财务数据CTMXCytomX Therapeutics Inc

Evaluating the bottom line, CytomX Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1677.08%, while the net margin is -1457.40%. These profitability ratios, combined with a Return on Equity (ROE) of -39.18%, provide a clear picture of how effectively CTMX converts its operational activities into shareholder value.

In the context of the broader market, CTMX competes directly with industry leaders such as GYRE and PHAR. With a market capitalization of $799.69M, it holds a significant position in the sector. When comparing efficiency, CTMX's gross margin of 100.00% stands against GYRE's 92.41% and PHAR's N/A. Such benchmarking helps identify whether CytomX Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

CytomX reported a Q2 revenue of $1.42M, down 92.4% year-over-year, and a net income loss of -$20.67M, reflecting ongoing financial struggles. The gross margin remains strong at 100%, but the net margin is deeply negative, indicating profitability issues.